Episode 113: Decreased Fracture Rate by Mandating Bone Protecting Agents in the EORTC 1333/PEACEIII trial

Silke Gillessen gives a safety update from this EORTC study focusing on fractures. The randomized phase III EORTC-1333-GUCG (NCT02194842) trial compares enzalutamide vs. a combination of Radium 223 and enzalutamide in asymptomatic or mildly symptomatic metastatic castration resistant prostate cancer (mCRPC) patients

View the ASCO Abstract

Related Episodes

Episode 130: Larry Einhorn – The Uromigos Legends in GU Cancer series
Episode 129: Phil Kantoff – The Uromigos Legends in GU Cancer series
Episode 128: APCCC – PSA relapse post prostatectomy
Episode 127: APCCC – Adjuvant radiotherapy post prostatectomy
Episode 126: APCCC podcast – germ line testing and molecular testing in prostate cancer
Episode 125: The Uromigos Paper of the Month – MRI screening for prostate cancer
Episode 123: Maha Hussain – The Uromigos Legends in GU Cancer series
Episode 115: Triplet therapy for 1st line metastatic prostate cancer
Episode 114: Radionuclides Therapy in Prostate Cancer
Episode 112: Genomic classifier of high risk African American men with prostate cancer identifying a high-risk population